MedTrace Logo

Optimum Misoprostol Dose Prior to Office Hysteroscopy

NCT01612065 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2013-04-11

No results posted yet for this study

Summary

Misoprostol is an effective agent for cervical priming before office hysteroscopy, vaginal route is the best, optimum dose not yet known.

Conditions

  • Infertility
  • Abnormal Uterine and Vaginal Bleeding, Unspecified
  • Recurrent Abortion

Interventions

DRUG

Misoprostol

200 ug

DRUG

Misoprostol

Misoprostol vaginally, 400 ug

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Waleed El-khayat, M.D. · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612065 on ClinicalTrials.gov